Review



human dermal microvascular endothelial cells cell line  (PromoCell)


Bioz Verified Symbol PromoCell is a verified supplier
Bioz Manufacturer Symbol PromoCell manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 95

    Structured Review

    PromoCell human dermal microvascular endothelial cells cell line
    Human Dermal Microvascular Endothelial Cells Cell Line, supplied by PromoCell, used in various techniques. Bioz Stars score: 95/100, based on 112 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+dermal+microvascular+endothelial+cells+cell+line/HDMEC-c+Human+Dermal+Microvascular+Endothelial+Cells/pmc12783151-367-0-20
    Average 95 stars, based on 112 article reviews
    human dermal microvascular endothelial cells cell line - by Bioz Stars, 2026-09
    95/100 stars

    Images

    Related Articles

    Cell Culture:

    Article Title: Comparative analysis of liquid and gel platelet rich plasma from apheresis and buffy coat in wound healing
    Article Snippet: HaCaT cells were cultured and seeded in standard DMEM, at 24 h from seeding DMEM was replaced by fresh standard DMEM or DMEM Low Ca 2+ (Gibco, USA), in order to obtain HaCaT with differentiated and basal phenotype respectively and treated with PRPs. .. Human Dermal Microvascular Endothelial Cells cell line (HDMEC, Cat.No.C-12212PromoCell, Germany), were cultured in the Endothelial Cell Basal Medium MV (Cat.No.C-22220, PromoCell, Germany) supplemented with the Endothelial Cell Growth Medium MV Supplement Pack (Cat.No.C-39220, PromoCell, Germany) at 37 °C, 5% CO2. .. Cells were detached with Trypsin 0.025%—EDTA 0.25 mM (Thermo Fisher Scientific, USA).

    Article Title: Comparative analysis of liquid and gel platelet rich plasma from apheresis and buffy coat in wound healing.
    Article Snippet: AR TIC LE IN PR ES S HaCaT cells were cultured and seeded in standard DMEM, at 24h from seeding DMEM was replaced by fresh standard DMEM or DMEM Low Ca2+ (Gibco, USA), in order to obtain HaCaT with differentiated and basal phenotype respectively and treated with PRPs. .. Human Dermal Microvascular Endothelial Cells cell line (HDMEC, Cat.No.C-12212PromoCell, Germany), were cultured in the Endothelial Cell Basal Medium MV (Cat.No.C-22220, PromoCell, Germany) supplemented with the Endothelial Cell Growth Medium MV Supplement Pack (Cat.No.C-39220, PromoCell, Germany) at 37°C, 5% CO2. .. Cells were detached with Trypsin 0.025% - EDTA 0.25 mM (Thermo Fisher Scientific, USA).



    Similar Products

    96
    ATCC cell lines human umbilical vein endothelial cells huvecs atcc pcs 100 010 human dermal microvascular endothelial cells
    Cell Lines Human Umbilical Vein Endothelial Cells Huvecs Atcc Pcs 100 010 Human Dermal Microvascular Endothelial Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+dermal+microvascular+endothelial+cells+cell+line/Primary+Umbilical+Vein+Endothelial+Cells%3B+Normal%2C+Human/pm41411132-569-166-174
    Average 96 stars, based on 1 article reviews
    cell lines human umbilical vein endothelial cells huvecs atcc pcs 100 010 human dermal microvascular endothelial cells - by Bioz Stars, 2026-09
    96/100 stars
      Buy from Supplier

    95
    PromoCell human dermal microvascular endothelial cells cell line
    Human Dermal Microvascular Endothelial Cells Cell Line, supplied by PromoCell, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+dermal+microvascular+endothelial+cells+cell+line/HDMEC-c+Human+Dermal+Microvascular+Endothelial+Cells/pmc12783151-367-0-20
    Average 95 stars, based on 1 article reviews
    human dermal microvascular endothelial cells cell line - by Bioz Stars, 2026-09
    95/100 stars
      Buy from Supplier

    97
    ATCC human dermal microvascular endothelial cell line
    Effect of OA on viability and LDH release in human (HMEC-1) and mouse (MS1) <t>microvascular</t> <t>endothelial</t> cells. a Cell viability of HMEC-1 cells treated with OA for 3, 6–24 h. b Cell viability of MS1 cells treated with OA for 3, 6–24 h. Results are expressed as percentage of control cells and presented as mean ± SEM of three independent replicates performed by triplicate. c LDH release in HMEC-1 cells and d) MS1 cells treated with OA for 3, 6–24 h. Data are expressed as percentage of cell death control and presented as mean ± SEM of three independent replicates performed by duplicate. Statistical differences were assessed by one-way ANOVA followed by Dunnett’s tests (* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 compared to untreated control).
    Human Dermal Microvascular Endothelial Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+dermal+microvascular+endothelial+cells+cell+line/HMEC-1/pmc13086646-51-0-10
    Average 97 stars, based on 1 article reviews
    human dermal microvascular endothelial cell line - by Bioz Stars, 2026-09
    97/100 stars
      Buy from Supplier

    95
    ATCC human microvascular endothelial cell line
    Effect of OA on viability and LDH release in human (HMEC-1) and mouse (MS1) <t>microvascular</t> <t>endothelial</t> cells. a Cell viability of HMEC-1 cells treated with OA for 3, 6–24 h. b Cell viability of MS1 cells treated with OA for 3, 6–24 h. Results are expressed as percentage of control cells and presented as mean ± SEM of three independent replicates performed by triplicate. c LDH release in HMEC-1 cells and d) MS1 cells treated with OA for 3, 6–24 h. Data are expressed as percentage of cell death control and presented as mean ± SEM of three independent replicates performed by duplicate. Statistical differences were assessed by one-way ANOVA followed by Dunnett’s tests (* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 compared to untreated control).
    Human Microvascular Endothelial Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+dermal+microvascular+endothelial+cells+cell+line/TIME%3B+Dermal+Endothelial+Cells%3B+Human/us12285422-129-1-10
    Average 95 stars, based on 1 article reviews
    human microvascular endothelial cell line - by Bioz Stars, 2026-09
    95/100 stars
      Buy from Supplier

    94
    ATCC human dermal microvascular endothelial cell lines
    Effect of OA on viability and LDH release in human (HMEC-1) and mouse (MS1) <t>microvascular</t> <t>endothelial</t> cells. a Cell viability of HMEC-1 cells treated with OA for 3, 6–24 h. b Cell viability of MS1 cells treated with OA for 3, 6–24 h. Results are expressed as percentage of control cells and presented as mean ± SEM of three independent replicates performed by triplicate. c LDH release in HMEC-1 cells and d) MS1 cells treated with OA for 3, 6–24 h. Data are expressed as percentage of cell death control and presented as mean ± SEM of three independent replicates performed by duplicate. Statistical differences were assessed by one-way ANOVA followed by Dunnett’s tests (* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 compared to untreated control).
    Human Dermal Microvascular Endothelial Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+dermal+microvascular+endothelial+cells+cell+line/TIME-GFP/pmc12022696-154-0-8
    Average 94 stars, based on 1 article reviews
    human dermal microvascular endothelial cell lines - by Bioz Stars, 2026-09
    94/100 stars
      Buy from Supplier

    90
    Separation Scientific SA human dermal microvascular endothelial cell line hmec-1
    Effect of OA on viability and LDH release in human (HMEC-1) and mouse (MS1) <t>microvascular</t> <t>endothelial</t> cells. a Cell viability of HMEC-1 cells treated with OA for 3, 6–24 h. b Cell viability of MS1 cells treated with OA for 3, 6–24 h. Results are expressed as percentage of control cells and presented as mean ± SEM of three independent replicates performed by triplicate. c LDH release in HMEC-1 cells and d) MS1 cells treated with OA for 3, 6–24 h. Data are expressed as percentage of cell death control and presented as mean ± SEM of three independent replicates performed by duplicate. Statistical differences were assessed by one-way ANOVA followed by Dunnett’s tests (* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 compared to untreated control).
    Human Dermal Microvascular Endothelial Cell Line Hmec 1, supplied by Separation Scientific SA, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+dermal+microvascular+endothelial+cells+cell+line/human+dermal+microvascular+endothelial+cell+line+hmec+1/pm37384895-219-2-8
    Average 90 stars, based on 1 article reviews
    human dermal microvascular endothelial cell line hmec-1 - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    95
    ATCC dermal microvascular endothelial cell line ihdmec time
    ( a ) Tumor growth curves (i – iii) and (iv) summary of relative final tumor volumes of HS-PDXs with the indicate EC/EPC sources. TC + CA-MSC in the absence or presence of human EC (TC + CA-MSC; n = 6) <t>(iHDMEC</t> + iHUVEC) and Pt. EC/EPC (TC + CA-MSC + EC/EPC; n = 7). ( b ) IF evaluation of human tumor vascular antigen CD31 (red) in PDXs with the indicated EC/EPC sources. 4′,6-diamidino-2-phenylindole (DAPI; blue) is used to label cell nuclei. ( c ) IF evaluation of a tumor specific vascular marker EGFL6 (red). Cell nuclei were counterstained with DAPI (blue). ( d ) RNASeq based relative mRNA expression for two patient PDXs without and with the addition of human <t>endothelial</t> cells. (e) Growth curves for standard PDX and HS-PDX, derived from a patient with platinum refractory ovarian cancer, treated with carboplatin (blue arrows indicate timing of carboplatin administration. Abbreviations : CA-MSC, cancer-associated mesenchymal stem cells; EC, endothelial cells; EPC, endothelial progenitor cells; iHDMEC, immortalized human dermal <t>microvascular</t> endothelial cells; iHUVEC, immortalized human umbilical vein endothelial cells; PDX, patient-derived xenograft; P0 and P1, passage 0 and passage 1 (The first generation of PDX is denoted P0, and P0 is subsequently passaged to second generation (P1); Pt., patient; TC, tumor cells. * p < 0.05, ** p < 0.01, *** p < 0.001. Scale bars, 20 µm.
    Dermal Microvascular Endothelial Cell Line Ihdmec Time, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+dermal+microvascular+endothelial+cells+cell+line/TIME%3B+Dermal+Endothelial+Cells%3B+Human/bio_rxiv__2023__07__03__547206-190-2-9
    Average 95 stars, based on 1 article reviews
    dermal microvascular endothelial cell line ihdmec time - by Bioz Stars, 2026-09
    95/100 stars
      Buy from Supplier

    91
    ATCC dermal microvascular endothelial cell line nfkb time
    ( a ) Tumor growth curves (i – iii) and (iv) summary of relative final tumor volumes of HS-PDXs with the indicate EC/EPC sources. TC + CA-MSC in the absence or presence of human EC (TC + CA-MSC; n = 6) <t>(iHDMEC</t> + iHUVEC) and Pt. EC/EPC (TC + CA-MSC + EC/EPC; n = 7). ( b ) IF evaluation of human tumor vascular antigen CD31 (red) in PDXs with the indicated EC/EPC sources. 4′,6-diamidino-2-phenylindole (DAPI; blue) is used to label cell nuclei. ( c ) IF evaluation of a tumor specific vascular marker EGFL6 (red). Cell nuclei were counterstained with DAPI (blue). ( d ) RNASeq based relative mRNA expression for two patient PDXs without and with the addition of human <t>endothelial</t> cells. (e) Growth curves for standard PDX and HS-PDX, derived from a patient with platinum refractory ovarian cancer, treated with carboplatin (blue arrows indicate timing of carboplatin administration. Abbreviations : CA-MSC, cancer-associated mesenchymal stem cells; EC, endothelial cells; EPC, endothelial progenitor cells; iHDMEC, immortalized human dermal <t>microvascular</t> endothelial cells; iHUVEC, immortalized human umbilical vein endothelial cells; PDX, patient-derived xenograft; P0 and P1, passage 0 and passage 1 (The first generation of PDX is denoted P0, and P0 is subsequently passaged to second generation (P1); Pt., patient; TC, tumor cells. * p < 0.05, ** p < 0.01, *** p < 0.001. Scale bars, 20 µm.
    Dermal Microvascular Endothelial Cell Line Nfkb Time, supplied by ATCC, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+dermal+microvascular+endothelial+cells+cell+line/NFkB-TIME%3B+Dermal+Endothelial+Cells%3B+Human/pm37184230-54-13-22
    Average 91 stars, based on 1 article reviews
    dermal microvascular endothelial cell line nfkb time - by Bioz Stars, 2026-09
    91/100 stars
      Buy from Supplier

    Image Search Results


    Effect of OA on viability and LDH release in human (HMEC-1) and mouse (MS1) microvascular endothelial cells. a Cell viability of HMEC-1 cells treated with OA for 3, 6–24 h. b Cell viability of MS1 cells treated with OA for 3, 6–24 h. Results are expressed as percentage of control cells and presented as mean ± SEM of three independent replicates performed by triplicate. c LDH release in HMEC-1 cells and d) MS1 cells treated with OA for 3, 6–24 h. Data are expressed as percentage of cell death control and presented as mean ± SEM of three independent replicates performed by duplicate. Statistical differences were assessed by one-way ANOVA followed by Dunnett’s tests (* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 compared to untreated control).

    Journal: Archives of Toxicology

    Article Title: Okadaic acid triggers NFκB and STAT3 phosphorylation followed by a release of inflammatory markers in human and mouse endothelial cells

    doi: 10.1007/s00204-026-04320-3

    Figure Lengend Snippet: Effect of OA on viability and LDH release in human (HMEC-1) and mouse (MS1) microvascular endothelial cells. a Cell viability of HMEC-1 cells treated with OA for 3, 6–24 h. b Cell viability of MS1 cells treated with OA for 3, 6–24 h. Results are expressed as percentage of control cells and presented as mean ± SEM of three independent replicates performed by triplicate. c LDH release in HMEC-1 cells and d) MS1 cells treated with OA for 3, 6–24 h. Data are expressed as percentage of cell death control and presented as mean ± SEM of three independent replicates performed by duplicate. Statistical differences were assessed by one-way ANOVA followed by Dunnett’s tests (* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 compared to untreated control).

    Article Snippet: Human dermal microvascular endothelial cell line (HMEC-1) was obtained from American Type Culture Collection (ATCC), number CRL 3243.

    Techniques: Control

    Measurement of IL-6 and CD147 release from human (HMEC-1) and mouse (MS1) microvascular endothelial cells treated with OA. a IL-6 release in HMEC-1 and b IL-6 release in MS1 after OA treatment. c Levels of CD147 receptor measured in HMEC-1. d Levels of CD147 receptor measured in MS1. LPS at 500 ng/ml was used as a positive control. Mean ± SEM of three independent replicates performed by duplicate. Statistical differences were assessed by one-way ANOVA followed by Dunnett’s tests (* p < 0.05, ** p < 0.01, *** p < 0.001 **** p < 0.0001 compared to untreated control.

    Journal: Archives of Toxicology

    Article Title: Okadaic acid triggers NFκB and STAT3 phosphorylation followed by a release of inflammatory markers in human and mouse endothelial cells

    doi: 10.1007/s00204-026-04320-3

    Figure Lengend Snippet: Measurement of IL-6 and CD147 release from human (HMEC-1) and mouse (MS1) microvascular endothelial cells treated with OA. a IL-6 release in HMEC-1 and b IL-6 release in MS1 after OA treatment. c Levels of CD147 receptor measured in HMEC-1. d Levels of CD147 receptor measured in MS1. LPS at 500 ng/ml was used as a positive control. Mean ± SEM of three independent replicates performed by duplicate. Statistical differences were assessed by one-way ANOVA followed by Dunnett’s tests (* p < 0.05, ** p < 0.01, *** p < 0.001 **** p < 0.0001 compared to untreated control.

    Article Snippet: Human dermal microvascular endothelial cell line (HMEC-1) was obtained from American Type Culture Collection (ATCC), number CRL 3243.

    Techniques: Positive Control, Control

    Analysis of NFκB and STAT3 activation in human (HMEC-1) and mouse (MS1) microvascular endothelial cells after treatment with OA. a Activation of NFκB-p65 in HMEC-1 cells and b activation of NFκB-p65 in MS1 cells. c Activation of STAT3 in HMEC-1 and d activation of STAT3 in MS1 cells. Data are present as ratio of phosphorylated and total protein and normalized by actin. Cells were incubated with 100 nM OA for 3 and 6 h. LPS 500 ng/mL was used as positive control. Mean ± SEM from three independent replicates performed in duplicate. Statistical differences were assessed by one-way ANOVA followed by Dunnett’s tests (* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 compared to untreated control).

    Journal: Archives of Toxicology

    Article Title: Okadaic acid triggers NFκB and STAT3 phosphorylation followed by a release of inflammatory markers in human and mouse endothelial cells

    doi: 10.1007/s00204-026-04320-3

    Figure Lengend Snippet: Analysis of NFκB and STAT3 activation in human (HMEC-1) and mouse (MS1) microvascular endothelial cells after treatment with OA. a Activation of NFκB-p65 in HMEC-1 cells and b activation of NFκB-p65 in MS1 cells. c Activation of STAT3 in HMEC-1 and d activation of STAT3 in MS1 cells. Data are present as ratio of phosphorylated and total protein and normalized by actin. Cells were incubated with 100 nM OA for 3 and 6 h. LPS 500 ng/mL was used as positive control. Mean ± SEM from three independent replicates performed in duplicate. Statistical differences were assessed by one-way ANOVA followed by Dunnett’s tests (* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 compared to untreated control).

    Article Snippet: Human dermal microvascular endothelial cell line (HMEC-1) was obtained from American Type Culture Collection (ATCC), number CRL 3243.

    Techniques: Activation Assay, Incubation, Positive Control, Control

    ( a ) Tumor growth curves (i – iii) and (iv) summary of relative final tumor volumes of HS-PDXs with the indicate EC/EPC sources. TC + CA-MSC in the absence or presence of human EC (TC + CA-MSC; n = 6) (iHDMEC + iHUVEC) and Pt. EC/EPC (TC + CA-MSC + EC/EPC; n = 7). ( b ) IF evaluation of human tumor vascular antigen CD31 (red) in PDXs with the indicated EC/EPC sources. 4′,6-diamidino-2-phenylindole (DAPI; blue) is used to label cell nuclei. ( c ) IF evaluation of a tumor specific vascular marker EGFL6 (red). Cell nuclei were counterstained with DAPI (blue). ( d ) RNASeq based relative mRNA expression for two patient PDXs without and with the addition of human endothelial cells. (e) Growth curves for standard PDX and HS-PDX, derived from a patient with platinum refractory ovarian cancer, treated with carboplatin (blue arrows indicate timing of carboplatin administration. Abbreviations : CA-MSC, cancer-associated mesenchymal stem cells; EC, endothelial cells; EPC, endothelial progenitor cells; iHDMEC, immortalized human dermal microvascular endothelial cells; iHUVEC, immortalized human umbilical vein endothelial cells; PDX, patient-derived xenograft; P0 and P1, passage 0 and passage 1 (The first generation of PDX is denoted P0, and P0 is subsequently passaged to second generation (P1); Pt., patient; TC, tumor cells. * p < 0.05, ** p < 0.01, *** p < 0.001. Scale bars, 20 µm.

    Journal: bioRxiv

    Article Title: A Novel Humanized Immune Stroma PDX Cancer Model for Therapeutic Studies

    doi: 10.1101/2023.07.03.547206

    Figure Lengend Snippet: ( a ) Tumor growth curves (i – iii) and (iv) summary of relative final tumor volumes of HS-PDXs with the indicate EC/EPC sources. TC + CA-MSC in the absence or presence of human EC (TC + CA-MSC; n = 6) (iHDMEC + iHUVEC) and Pt. EC/EPC (TC + CA-MSC + EC/EPC; n = 7). ( b ) IF evaluation of human tumor vascular antigen CD31 (red) in PDXs with the indicated EC/EPC sources. 4′,6-diamidino-2-phenylindole (DAPI; blue) is used to label cell nuclei. ( c ) IF evaluation of a tumor specific vascular marker EGFL6 (red). Cell nuclei were counterstained with DAPI (blue). ( d ) RNASeq based relative mRNA expression for two patient PDXs without and with the addition of human endothelial cells. (e) Growth curves for standard PDX and HS-PDX, derived from a patient with platinum refractory ovarian cancer, treated with carboplatin (blue arrows indicate timing of carboplatin administration. Abbreviations : CA-MSC, cancer-associated mesenchymal stem cells; EC, endothelial cells; EPC, endothelial progenitor cells; iHDMEC, immortalized human dermal microvascular endothelial cells; iHUVEC, immortalized human umbilical vein endothelial cells; PDX, patient-derived xenograft; P0 and P1, passage 0 and passage 1 (The first generation of PDX is denoted P0, and P0 is subsequently passaged to second generation (P1); Pt., patient; TC, tumor cells. * p < 0.05, ** p < 0.01, *** p < 0.001. Scale bars, 20 µm.

    Article Snippet: Immortalized human dermal microvascular endothelial cell line (iHDMEC) TIME (ATCC ® CRL-4025TM), and immortalized human umbilical vein endothelial cell line (iHUVEC) HUVEC/TERT 2 (ATCC ® CRL-4053) were purchased from ATCC (Manassas, VA, USA).

    Techniques: Marker, Expressing, Derivative Assay

    HIS-PDX were created by co-engraftment of PDX TC, CA-MSC and EC (iHUVEC + iHDMEC). ( a ) IF for alpha smooth muscle actin (αSMA; red), and human-specific mitochondrial antigen (hMitoc; green) or pan-cytokeratin (PanCK; green) to label tumor cells in standard and HIS-PDX. Cell nuclei are counterstained with DAPI (blue). ( b ) Hematoxylin and eosin (H&E) staining for a cell line derived xenografts, standard PDX, humanized immune stroma PDX (HIS-PDX) and matched patient’s primary tumor. ( c ) RNA-seq derived heat map for stromal and immune gene expression in solid tumor derived standard PDXs (StndPDX), HIS-PDX, and patient primary tumor. ( d ) Total gene expression correlation between primary human tumor and HIS-PDX. Scale bars in ( a ), 20 µm; scale bars in ( b ), 200 µm.

    Journal: bioRxiv

    Article Title: A Novel Humanized Immune Stroma PDX Cancer Model for Therapeutic Studies

    doi: 10.1101/2023.07.03.547206

    Figure Lengend Snippet: HIS-PDX were created by co-engraftment of PDX TC, CA-MSC and EC (iHUVEC + iHDMEC). ( a ) IF for alpha smooth muscle actin (αSMA; red), and human-specific mitochondrial antigen (hMitoc; green) or pan-cytokeratin (PanCK; green) to label tumor cells in standard and HIS-PDX. Cell nuclei are counterstained with DAPI (blue). ( b ) Hematoxylin and eosin (H&E) staining for a cell line derived xenografts, standard PDX, humanized immune stroma PDX (HIS-PDX) and matched patient’s primary tumor. ( c ) RNA-seq derived heat map for stromal and immune gene expression in solid tumor derived standard PDXs (StndPDX), HIS-PDX, and patient primary tumor. ( d ) Total gene expression correlation between primary human tumor and HIS-PDX. Scale bars in ( a ), 20 µm; scale bars in ( b ), 200 µm.

    Article Snippet: Immortalized human dermal microvascular endothelial cell line (iHDMEC) TIME (ATCC ® CRL-4025TM), and immortalized human umbilical vein endothelial cell line (iHUVEC) HUVEC/TERT 2 (ATCC ® CRL-4053) were purchased from ATCC (Manassas, VA, USA).

    Techniques: Staining, Derivative Assay, RNA Sequencing, Gene Expression